RT Journal Article
T1 Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging
A1 Sullivan, Frank M.
A1 Mair, Frances S.
A1 Anderson, William
A1 Armory, Pauline
A1 Briggs, Andrew
A1 Chew, Cindy
A1 Dorward, Alistair
A1 Haughney, John
A1 Hogarth, Fiona
A1 Kendrick, Denise
A1 Littleford, Roberta
A1 McConnachie, Alex
A1 McCowan, Colin
A1 McMeekin, Nicola
A1 Patel, Manish
A1 Rauchhaus, Petra
A1 Ritchie, Lewis
A1 Robertson, Chris
A1 Robertson, John
A1 Robles-Zurita, José Antonio
A1 Sarvesvaran, Joseph
A1 Sewell, Herbert
A1 Sproule, Michael
A1 Taylor, Thomas
A1 Tello, Agnes
A1 Treweek, Shaun
A1 Vedhara, Kavita
A1 Schembri, Stuart
K1 Pulmón - Cáncer - Diagnóstico
AB The EarlyCDT-Lung test is a high-specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. We report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent computed tomography (CT) scanning to identify those at high risk of lung cancer reduces the incidence of patients with stage III/IV/unspecified lung cancer at diagnosis compared with the standard clinical practice at the time the study began.The Early Diagnosis of Lung Cancer Scotland (ECLS) trial was a randomised controlled trial of 12 208 participants at risk of developing lung cancer in Scotland in the UK. The intervention arm received the EarlyCDT-Lung test and, if test-positive, low-dose CT scanning 6-monthly for up to 2 years. EarlyCDT-Lung test-negative and control arm participants received standard clinical care. Outcomes were assessed at 2 years post-randomisation using validated data on cancer occurrence, cancer staging, mortality and comorbidities.At 2 years, 127 lung cancers were detected in the study population (1.0%). In the intervention arm, 33 out of 56 (58.9%) lung cancers were diagnosed at stage III/IV compared with 52 out of 71 (73.2%) in the control arm. The hazard ratio for stage III/IV presentation was 0.64 (95% CI 0.41–0.99). There were nonsignificant differences in lung cancer and all-cause mortality after 2 years.ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic presentation) and was not designed to assess the incremental contribution of the EarlyCDT-Lung test. The observation of a stage shift towards earlier-stage lung cancer diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds anything to the emerging standard of low-dose CT.
PB EUROPEAN RESPIRATORY SOC JOURNALS LTD
YR 2020
FD 2020
LK https://hdl.handle.net/10630/37236
UL https://hdl.handle.net/10630/37236
LA eng
NO Sullivan, F. M., Mair, F. S., Anderson, W., Armory, P., Briggs, A., Chew, C., ... & Schembri, S. (2021). Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1).
NO Funding has been received from the Scottish Government Health and Social Care Directorate and Oncimmune. Funding information for this article has been deposited with the Crossref Funder Registry.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 27 feb 2026